AJP - Regu Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Regul Integr Comp Physiol 293: R686-R694, 2007. First published May 2, 2007; doi:10.1152/ajpregu.00612.2006
0363-6119/07 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
293/2/R686    most recent
00612.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stupka, N.
Right arrow Articles by Lynch, G. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stupka, N.
Right arrow Articles by Lynch, G. S.

INFLAMMATION AND CYTOKINES

Calcineurin-A{alpha} activation enhances the structure and function of regenerating muscles after myotoxic injury

Nicole Stupka,1 Jonathan D. Schertzer,1 Rhonda Bassel-Duby,2 Eric N. Olson,2 and Gordon S. Lynch1

1Basic and Clinical Myology Laboratory, Department of Physiology, The University of Melbourne, Victoria, Australia; and 2University of Texas Southwestern Medical Center, Dallas, Texas

Submitted 27 August 2006 ; accepted in final form 29 April 2007


    ABSTRACT
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Calcineurin signaling is essential for successful muscle regeneration. Although calcineurin inhibition compromises muscle repair, it is not known whether calcineurin activation can enhance muscle repair after injury. Tibialis anterior (TA) muscles from adult wild-type (WT) and transgenic mice overexpressing the constitutively active calcineurin-A{alpha} transgene under the control of the mitochondrial creatine kinase promoter (MCK-CnA{alpha}*) were injected with the myotoxic snake venom Notexin to destroy all muscle fibers. The TA muscle of the contralateral limb served as the uninjured control. Muscle structure was assessed at 5 and 9 days postinjury, and muscle function was tested in situ at 9 days postinjury. Calcineurin stimulation enhanced muscle regeneration and altered levels of myoregulatory factors (MRFs). Recovery of myofiber size and force-producing capacity was hastened in injured muscles of MCK-CnA{alpha}* mice compared with control. Myogenin levels were greater 5 days postinjury and myocyte enhancer factor 2a (MEF2a) expression was greater 9 days postinjury in muscles of MCK-CnA{alpha}* mice compared with WT mice. Higher MEF2a expression in regenerating muscles of MCK-CnA{alpha}* mice 9 days postinjury may be related to an increase of slow fiber genes. Calcineurin activation in uninjured and injured TA muscles slowed muscle contractile properties, reduced fatigability, and enhanced force recovery after 4 min of intermittent maximal stimulation. Therefore, calcineurin activation can confer structural and functional benefits to regenerating skeletal muscles, which may be mediated in part by differential expression of MRFs.

myotoxic injury; skeletal muscle; muscle function


CALCINEURIN IS A SERINE/THREONINE phosphatase enzyme that regulates transcription by sensing changes in intracellular calcium-calmodulin concentrations (32). The calcineurin signal transduction pathway is important in skeletal muscle biology, because it can regulate the slow oxidative phenotype, regeneration, and myofiber growth (11, 16, 29). In animal models, pharmacological inhibition of calcineurin impairs skeletal muscle regeneration after injury (1, 38), and in regenerating muscles of young mdx dystrophic mice, it can severely compromise muscle structure and function (44). The effect of calcineurin stimulation on muscle regeneration efficacy is unknown.

Calcineurin controls satellite cell differentiation and myofiber growth and maturation. Activated calcineurin promotes the transcription and activation of myoregulatory factors (MRFs), myocyte enhancer factor 2 (MEF2), myogenin, and MyoD, either directly or in conjunction with nuclear factor of activated T cells (NFAT) (6, 11, 12, 38). The NFATc1, -c2, and -c3 isoforms are expressed in skeletal muscle (15) and have been observed in the cytoplasm of muscle cells at all stages of development (1). Specificity may exist among the NFAT isoforms in gene regulation, since each isoform has been shown to translocate to the nucleus at specific stages of muscle differentiation (1). Myogenin, MyoD, and MEF2 stimulate the differentiation of satellite cells and the maturation of myoblasts into myotubes (30). MEF2a also regulates the expression of the developmental myosin heavy chain (MyHC) isoform in newly regenerated fibers (35) and slow fiber-type-specific genes (49). In maturing muscle fibers, calcineurin can alter the expression of adult type I and IIa MyHC isoforms (2, 48).

Calcineurin has been implicated in regulating myofiber growth, and a positive relationship between calcineurin activation and muscle hypertrophy has been demonstrated (25). In myocyte cultures, calcineurin activation enhanced myotube formation (5). Cells expressing the activated calcineurin-A{alpha} (CnA{alpha}*) transgene were larger and contained more myonuclei, and MyHC protein and the hypertrophic response was associated with increased NFATc3 nuclear translocation (5). In vitro, IGF-I has been shown to activate calcineurin and its downstream transcription factors NFATc1 and GATA to stimulate myocyte hypertrophy (28, 42). Pharmacological inhibition of calcineurin prevented hypertrophy following functional overload of mouse plantaris muscle (9, 10). However, in vitro, the contribution of calcineurin signaling to muscle hypertrophy is influenced by experimental design (41). In experiments where the hypertrophic response depends on myoblast maturation and fusion (42) or the addition of myonuclei (26), the involvement of the calcineurin signal transduction pathway appears more definite. During development, myoblasts fuse to form nascent myotubes with a limited number of myonuclei. Further growth of these nascent myofibers depends on the fusion of additional myonuclei (16), and this can be controlled by calcineurin and NFATc2 (19). Activation and nuclear translocation of NFATc2 in nascent myotubes stimulates IL-4 transcription and synthesis (18). Secreted IL-4 is thought to bind to its receptor on myoblasts to initiate fusion of myoblasts to nascent myotubes (18). The physiological significance of this pathway has been demonstrated in cell cultures and NFATc2–/– knockout mice (16, 17, 19). In vivo, NFATc3 may regulate early events in primary myogenesis, given that muscles from NFATc3–/– knockout mice contain fewer myofibers than those from WT mice; however, mean fiber size is normal in these mice (21).

It is important to note that the effect of calcineurin activation on growth and hypertrophy is strongly influenced by muscle phenotype. Compared with wild-type (WT) mice, slow-twitch muscles (e.g., soleus) of mice overexpressing an activated form of calcineurin (MCK-CnA{alpha}*) have greater mass, and their mean fiber cross-sectional area is greater (47). However, fast-twitch muscles (e.g., tibialis anterior and medial gastrocnemius) of MCK-CnA{alpha}* mice have a smaller mass and fiber size compared with muscles from WT mice, and there is no change in mass or fiber size in muscles with an intermediate phenotype (e.g., plantaris) (47). Furthermore, genetic inhibition of calcineurin by muscle-specific overexpression of modulatory calcineurin-interacting protein 1 (MCIP1) reduced fiber size in slow-twitch soleus muscles by 30% but had no effect on fiber size in any other muscle type (31).

The aim of this study was to investigate whether expression of the constitutively active CnA{alpha}* transgene would improve muscle structure and function in regenerating muscles following myotoxic injury. It was hypothesized that increased calcineurin activity would hasten muscle regeneration by stimulating satellite cell differentiation and fusion of differentiated satellite cells to nascent myofibers, accelerating recovery of myofiber size. Furthermore, it was hypothesized that calcineurin activation would stimulate the maturation of newly regenerated myofibers, thus enhancing functional recovery.


    METHODS
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Transgenic mice. All experiments were approved by the Animal Experimentation Ethics Committee of The University of Melbourne. The MCK-CnA{alpha}* mice express an active from of calcineurin-A{alpha} (CnA{alpha}*). The CnA{alpha}* transgene is driven by the mitochondrial creatine kinase (MCK) promoter, which is induced during myogenic differentiation, and its activity is maximal in committed myotubes (43). The transgenic mice were developed at the Department of Molecular Biology at the University of Texas Southwestern Medical Center at Dallas (29). To generate the animals used in this study, the MCK-CnA{alpha}* mice, which have a B6C3F1 background, were mated with B6C3F1 WT mice. Half of the offspring expressed the CnA{alpha}* transgene (MCK-CnA{alpha}*), and the others were used as WT controls.

Mice that expressed the CnA{alpha}* transgene were identified through PCR screening of DNA extracted from tail tissue (29). Mice were maintained on a 12:12-h light-dark cycle, with standard mouse chow and water provided ad libitum. Assessments of tibialis anterior (TA) muscle function and regeneration were conducted on MCK-CnA{alpha}* and WT mice at 8.5 ± 0.8 mo of age.

Experimental injury. Muscle regeneration was assessed at 5 and 9 days postinjury. In the 5-day-postinjury group, the right TA was injured and the left TA muscle served as the uninjured control for assessment of muscle structure and function. In the 9-day-postinjury group, the left TA muscle was injured and used for muscle function testing and the right TA muscle served as the uninjured control. Histological and immunohistochemical analyses were performed on the injured and uninjured muscles at 5 and 9 days postinjury. Schertzer and Lynch (40) showed previously that after Notexin damage, muscle function can be measured reliably at 7 days postinjury. Before this time, the structural integrity of the degenerating-regenerating muscle does not permit consistent and reliable assessments of force-producing capacity. Mice were anesthetized with 100 mg/kg ketamine (Parnell Laboratories, Alexandria, NSW, Australia) and 10 mg/kg xylazine (Troy Laboratories, Smithfield, NSW, Australia) such that they were unresponsive to tactile stimuli. The appropriate (right or left) TA muscle was surgically exposed and injected to maximal holding capacity with the myotoxin Notexin (1.0 µg/ml, ~50 µl; Latoxan, Valence, France) through two injections in the proximal and distal regions of the muscle with a 30-gauge needle. The incision was closed with Michel clips (Aesculap, Tuttlingen, Germany), and the mice were kept warm on a heat pad and monitored closely until they regained consciousness. Injecting a muscle with Notexin destroys all mature muscle fibers but leaves satellite cells intact to facilitate muscle regeneration (14). The contralateral uninjured TA muscle was not injected with a saline vehicle, since previous studies have shown that injecting muscles with saline does not affect muscle function or structure (13, 20, 36).

Assessment of muscle function in situ. Details regarding the in situ TA muscle preparation and measurement of contractile properties have been described previously (7, 40). Briefly, the anesthetized mouse was placed on a heated (37°C) platform, the left foot of the mouse was secured to the platform, and the left knee was secured by pushing a sharpened pin attached to a clamp through the knee joint. The distal portion of the muscle and its tendon were dissected free and maintained at 37°C by incubating the exposed muscle in warmed mineral oil. The tendon was tied with 4-0 braided surgical silk to the lever arm of a dual-mode servomotor/force transducer (305-LR; Aurora Scientific, Aurora, ON, Canada). The muscle was stimulated maximally by directly applying supramaximal square wave pulses of 10 V, 300 ms in duration, to the exposed nerve (40). Optimum muscle length (Lo) was determined from micromanipulations of muscle length and a series of isometric twitch contractions. Maximum isometric tetanic force (Po) production was determined from the plateau of the frequency-force relationship. To assess fatigability, Po was determined once every 5 s for 4 min, and the muscle was then rested (no stimulation). Recovery of Po was determined at 1, 2, and 3 min after the fatigue protocol. Optimal fiber length (Lf) was determined by multiplying Lo by the TA Lf/Lo ratio of 0.6 (7).

After the final evaluation of Po, the TA muscle was carefully dissected from the mouse, trimmed of tendon and suture, and weighed on an analytical balance. The contralateral TA muscle was also excised. Both muscles were mounted separately in embedding medium, frozen in thawing isopentane, and stored at –80°C for later histological and immunohistochemical analyses. The mice were killed by cardiac excision while still anesthetized deeply. Muscle cross-sectional area was calculated by dividing muscle mass by the product of Lf and 1.06 mg/mm3, the density of mammalian skeletal muscle. Force per cross-sectional area, or specific force (sPo, kN/m2), was determined by dividing Po by muscle cross-sectional area (24).

Histology and immunohistochemistry. Four 5-µm-thick sections were cut from the midbelly region of each muscle on a cryostat at –20°C. The sections were air-dried overnight and stored at –80°C. One section was stained with hematoxylin and eosin (H&E) for determination of fiber cross-sectional area, muscle degeneration, and the proportion of centrally nucleated fibers, and the others were used for immunohistochemical analysis. Colored, digitized images of H&E-stained sections were captured with a digital camera (Spot, v2.2; Diagnostic Instruments, Sterling Heights, MI) mounted to an upright microscope (BX-51; Olympus, Tokyo, Japan) at x200 magnification for mean fiber cross-sectional analysis and at x100 magnification for assessment of TA muscle degeneration and regeneration and to determine the number of fibers per area (mm2) of tissue. Images were analyzed using an image analysis system (AIS, v6.0; Imaging Research, St. Catherines, ON, Canada). Mean fiber cross-sectional area was calculated by analyzing ~150 fibers per section. To quantitate regeneration efficacy in TA muscles at 9 days postinjury, areas of degeneration were identified and manually outlined using the image analysis program and expressed as a percentage of total section area examined; ~3 mm2 of muscle section were examined per sample.

Immunohistochemical techniques were used to assess markers of muscle regeneration in WT and MCK-CnA{alpha}* mice. Muscle sections were reacted with antibodies against myogenin (no. sc-576, diluted 1:60; Santa Cruz Biotechnology), MEF2a (no. sc-313, diluted 1:60; Santa Cruz Biotechnology), and the developmental MyHC isoform (no. NLC-MHCd, diluted 1:20; Novocastra) as described previously (45). The number of MEF2a- and myogenin-positive nuclei in each section was counted and expressed as the number of positive nuclei per area (mm2) of muscle. The number of muscle fibers that reacted with the anti-developmental MyHC antibody was counted and expressed as a proportion of the total number of muscle fibers (616 ± 50 fibers examined per section); their cross-sectional area was also determined. We reacted cross sections from uninjured muscles and from injured muscles at 5 and 9 days postinjury with the developmental MyHC antibody but did not present the 5-day-post injury data for two reasons. First, at 5 days postinjury, almost all of the fibers expressed the developmental MyHC, which made it difficult to discern the effect of calcineurin-A{alpha} activation on developmental MyHC expression. These fibers were (completely) stained red, unlike those from the 9-day-postinjury samples, in which some fibers had only partial staining for developmental MyHC. Second, the MyHC antibody (no. NLC-313; Novacastra) is a mouse monoclonal antibody, and the secondary rabbit anti-mouse antibody (no. E0464; Dako, Botany, Australia) can cross-react with endogenous mouse immunoglobulins (IgGs). Visualization of developmental MyHC staining on mouse muscle cross sections was achieved using a peroxidase detection system (Vectastain ABC kit, no. PK-6100; Vector Laboratories) and the AEC+ substrate chromogen (no. K3468; Dako) for color development. To control for nonspecific staining due to secondary antibody cross-reactivity, one negative control section from WT uninjured muscles incubated with the secondary antibody and the Vectastain kit and another negative control incubated with the Vectastain kit only were included with each staining run. In uninjured muscle sections from WT mice, nonspecific staining was minimal and confined to the interstitium and not the myofiber. At 5 days postinjury, there was still a considerable inflammatory response, with infiltration of neutrophils and macrophages to remove necrotic myofibers and promote regeneration. This was associated with increased IgG levels in the regenerating muscle and greater nonspecific staining in the interstitium, making it difficult to discern myoblast and regenerating fibers from inflammatory cells and cellular debris exposed to mouse IgGs. All sections for immunohistochemical analysis were counterstained with hematoxylin, which stained nuclei blue.

Statistics. Values are means ± SE. All statistical analyses were performed using a statistics software package (Minitab, State College, PA). ANOVA or two-sample t-tests were used to assess differences between uninjured and 5- or 9-day-postinjury TA muscles from MCK-CnA{alpha}* and WT mice. Tukey's post hoc test was used to locate pairwise significant differences, where appropriate. For all comparisons, P < 0.05 was considered significant.


    RESULTS
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Body and muscle mass of MCK-CnA{alpha}* mice. Body mass was similar in MCK-CnA{alpha}* and WT mice. TA muscles from MCK-CnA{alpha}* mice had a lower mass than those from WT mice (P < 0.05), and the muscle mass to body mass ratio (MM/BM) was lower (P < 0.05). Nine days after myotoxic injury, muscle mass from both strains was ~30% less than that of uninjured muscles and of injured muscles at 5 days postinjury (P < 0.05; Table 1).


View this table:
[in this window]
[in a new window]

 
Table 1. Muscle mass and contractile properties of uninjured and injured TA muscles

 
Muscle function is improved after injury in MCK-CnA{alpha}* mice. Twitch force (Pt) tended to be greater (~5%) in uninjured muscles from MCK-CnA{alpha}* than WT mice (P = 0.055). Nine days postinjury, Pt was ~35% that of uninjured Pt (P < 0.05). Po was ~20% lower in uninjured muscles from MCK-CnA{alpha}* than in those from WT mice (P < 0.05; main effect). Nine days post injury, Po was reduced by 71% compared with uninjured Po in MCK-CnA{alpha}* and WT mice (P < 0.05). Normalized force (sPo) of uninjured muscles from MCK-CnA{alpha}* mice was ~15% less than that of WT mice (P < 0.05). However, 9 days after injury, sPo of muscles from MCK-CnA{alpha}* and WT mice was similar: 44 and 35% of uninjured sPo, respectively (Table 1). Time to peak tension (TPT) and half-relaxation time (1/2RT) were prolonged in injured muscles (P < 0.05; main effect) and in muscles expressing the CnA{alpha}* transgene compared with WT mice (P < 0.05; Table 1).

Muscle fatigue is decreased in muscles of MCK-CnA{alpha}* mice. TA muscles of MCK-CnA{alpha}* mice fatigued less during 4 min of intermittent maximal stimulation and recovered their force-generating capacity better than muscles of WT mice (P < 0.05). At 2, 3, and 4 min into the fatigue protocol, relative Po was higher in muscles from MCK-CnA{alpha}* than in muscles from WT mice (P < 0.05). At 1, 2, and 3 min into recovery, Po of muscles from MCK-CnA{alpha}* mice had returned to initial values (time = 0 min of fatigue), whereas Po of muscles from WT mice never fully recovered (P < 0.05). Uninjured muscles tended to fatigue more than injured/regenerating muscles during the repeated stimulation protocol, but force recovery following the 4-min fatigue protocol tended to be superior than injured muscles (not significant; Fig. 1A). It should be noted that injured muscles produced less force than uninjured muscles during the fatigue protocol and recovery (Fig. 1B).


Figure 1
View larger version (18K):
[in this window]
[in a new window]

 
Fig. 1. Fatigability and recovery of force following repeated contractile activity in tibialis anterior (TA) muscles of mice overexpressing an activated form of calcineurin under the control of the mitochondrial creatine kinase promoter (MCK-CnA{alpha}* mice) and wild-type (WT) mice. A: relative change in force output of muscles following 4 min of intermittent determination of maximal isometric force (Po) and at 1, 2, and 3 min of recovery. Fatigue resistance and recovery of force were better in muscles of MCK-CnA{alpha}* than WT mice (main effect; P < 0.05). B: absolute change in force output following 4 min of repeated intermittent stimulation with determination of Po at 1, 2, and 3 min of the recovery period. Note that compared with uninjured muscles, injured muscles produced less force during repeated contractile activity and recovery. 9d, 9 days postinjury.

 
Muscle degeneration is decreased in MCK-CnA{alpha}* mice after injury. In uninjured muscles of MCK-CnA{alpha}* mice, mean fiber size was ~30% smaller than in WT mice (P < 0.05). Five days postinjury, mean fiber size was 23% of control values in muscles from WT and MCK-CnA{alpha}* mice. At 9 days postinjury, muscles from MCK-CnA{alpha}* mice recovered their mean (uninjured) fiber size to a greater extent than muscles from WT mice (49 vs. 39%) such that the difference in fiber size between MCK-CnA{alpha}* and WT mice was ~16% and no longer statistically significant (P > 0.05; Table 2). Muscle degeneration, defined as areas of connective tissue, fat, and mononuclear cell infiltration, was assessed at 9 days postinjury. In muscles of MCK-CnA{alpha}* mice, degeneration occupied 38% of the cross section analyzed, whereas in WT mice it was 51% (P < 0.05; Fig. 2, A and D).


View this table:
[in this window]
[in a new window]

 
Table 2. Muscle morphology of injured and uninjured TA muscles

 

Figure 2
View larger version (52K):
[in this window]
[in a new window]

 
Fig. 2. Muscle morphology of injured and uninjured TA muscles of MCK-CnA{alpha}* and WT mice. A: representative hematoxylin- and eosin-stained sections from uninjured muscles of MCK-CnA{alpha}* and WT mice and at 5 and 9 days postinjury. Scale bar represents 100 µm and applies to all panels. B: at 9 days postinjury, the number of central nuclei (CN) per myofiber was similar in muscles from MCK-CnA{alpha}* and WT mice. C: the number of muscle fibers was greater in uninjured and 9-day-postinjury muscles of MCK-CnA{alpha}* than WT mice (*P < 0.05; main effect). In muscles from MCK-CnA{alpha}* mice, the number of muscle fibers was greater at 9 days postinjury than in uninjured muscles ({dagger}P < 0.05; strain x time interaction). D: at 9 days postinjury, the proportion of the muscle cross section occupied by mononuclear, adipose, and connective tissue infiltration was greater in WT than in MCK-CnA{alpha}* mice (*P < 0.05).

 
Expression of the CnA{alpha}* transgene appeared to increase myofiber number in uninjured and regenerating muscles (P < 0.05), with the number of fibers per area (mm2) of tissue being 42% greater in uninjured muscles and 33% greater in muscles of MCK-CnA{alpha}* mice compared with WT mice at 9 days postinjury. In both MCK-CnA{alpha}* and WT mice, the number of muscle fibers was higher in injured than in uninjured muscle (P < 0.05; Fig. 2C).

Expression of myogenic markers is increased in MCK-CnA{alpha}* mice during early regeneration. In WT and MCK-CnA{alpha}* mice, the number of myogenin- and MEF2a-positive nuclei was significantly higher in injured than in uninjured TA muscles (P < 0.05; Figs. 3 and 4). Five days postinjury, myogenin expression was higher in muscles of MCK-CnA{alpha}* than WT mice (P < 0.05). Between 5 and 9 days postinjury, myogenin expression was decreased approximately fourfold in muscles of MCK-CnA{alpha}* and approximately twofold in muscles of WT mice such that by 9 days postinjury, myogenin expression was similar in both strains (Fig. 3). Similarly, the number of myogenin-positive nuclei per muscle fiber (as assessed in cross section) was lower in the muscles of MCK-CnA{alpha}* compared with WT mice at 9 days postinjury (data not shown). At 9 days postinjury, the number of MEF2a-positive nuclei was higher in muscles of MCK-CnA{alpha}* than in WT mice (P < 0.05; strain x injury interaction; Fig. 4), but not when the number of MEF2a-positive nuclei was expressed per myofiber (data not shown). MEF2a expression was highest 9 days postinjury in MCK-CnA{alpha}* mice (P < 0.05) and 5 days postinjury in WT mice (P = 0.09).


Figure 3
View larger version (43K):
[in this window]
[in a new window]

 
Fig. 3. Myogenin expression in uninjured and injured TA muscles of MCK-CnA{alpha}* and WT mice. A: representative cross sections of uninjured and injured (5 and 9 days postinjury) muscles of MCK-CnA{alpha}* and WT mice, reacted with an antibody against myogenin. Arrows indicate myogenin-positive nuclei. Scale bar represents 100 µm and applies to all panels. B: relative to uninjured muscles, myogenin expression was greater at 5 days compared with 9 days postinjury in WT and MCK-CnA{alpha}* mice (*{dagger}P < 0.05, strain x time interaction). At 5 days postinjury, the number of myogenin-positive nuclei was greater in muscles of MCK-CnA{alpha}* than WT mice ({ddagger}P < 0.05; strain x time interaction). By 9 days postinjury, myogenin expression was similar in muscles of WT and MCK-CnA{alpha}* mice.

 

Figure 4
View larger version (43K):
[in this window]
[in a new window]

 
Fig. 4. Myocyte enhancer factor 2a (MEF2a) expression in uninjured and injured TA muscles of MCK-CnA{alpha}* and WT mice. A: representative cross sections of uninjured and injured (5 and 9 days postinjury) muscles of MCK-CnA{alpha}* and WT mice, reacted with an antibody against MEF2a. Arrows indicate MEF2a-positive nuclei. Scale bar represents 100 µm and applies to all panels. B: MEF2a expression was greater in injured than uninjured muscles of WT and MCK-CnA{alpha}* mice (*{dagger}P < 0.05; strain x time interaction). At 9 days postinjury, the number of MEF2a-positive nuclei was higher in muscles of MCK-CnA{alpha}* than WT mice ({ddagger}P < 0.05; strain x time interaction). Furthermore, in muscles from MCK-CnA{alpha}* mice, MEF2a expression was greater at 9 than at 5 days postinjury (§P < 0.05; strain x time interaction).

 
At 9 days postinjury, the proportion of centrally nucleated fibers and the number of central nuclei per fiber were similar in muscles from MCK-CnA{alpha}* and WT mice (Fig. 2B). The proportion of fibers expressing the developmental MyHC isoform was higher in injured than in uninjured muscles (P < 0.05) and similar in regenerating muscles from MCK-CnA{alpha}* and WT mice (Fig. 5).


Figure 5
View larger version (44K):
[in this window]
[in a new window]

 
Fig. 5. Developmental myosin heavy chain (MyHC) isoform expression in uninjured and injured TA muscles of MCK-CnA{alpha}* and WT mice. A: representative cross sections of uninjured and injured (9 days postinjury) muscles of MCK-CnA{alpha}* and WT mice, reacted with an antibody against developmental MyHC. Fibers that reacted with the antibody stained red and are indicated with arrows. Note that all sections were counterstained with hematoxylin, which stained nuclei blue. Scale bar represents 100 µm and applies to all panels. B: developmental MyHC expression was greater in injured than in uninjured muscles of WT and MCK-CnA{alpha}* mice (*{dagger}P < 0.05; main effect).

 

    DISCUSSION
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Calcineurin activation was associated with the upregulation of specific MRFs in regenerating skeletal muscles. Five days post myotoxic injury, myogenin expression was greater and 9 days postinjury, MEF2a levels were greater in muscles from MCK-CnA{alpha}* mice than in WT mice. The alterations in MRFs were associated with the enhanced regeneration and maturation of myofibers, since at 9 days postinjury, recovery of fiber size, overall muscle architecture, and relative normalized force-producing capacity were superior in muscles from MCK-CnA{alpha}* mice compared with WT mice.

Calcineurin activation causes a shift to a slower muscle phenotype (22, 29, 47) and an increased expression of type IIa and I MyHC isoforms and the slow sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) 2a isoform in skeletal muscle (3, 4). These effects were associated with concomitant changes in muscle function (46). Similarly, in the present study, twitch contraction time (TPT) and relaxation time (1/2RT) were prolonged in TA muscles of MCK-CnA{alpha}* compared with WT mice. Consistent with a slower phenotype, muscles from MCK-CnA{alpha}* mice had an altered twitch/tetanus ratio, fatigued less during repeated contractile activity, and exhibited an improved force recovery. The shift to a slower phenotype reduced the force-producing capacity, as evident from the ~20% decrease in Po and ~15% decrease in sPo in muscles of MCK-CnA{alpha}* mice. These changes were attributed to the ~15% decrease in muscle mass and ~30% decrease in fiber size. In TA muscles of MCK-CnA{alpha}* mice, the decrease in fiber size was twofold greater than the decrease in muscle mass. This can be accounted for by the 42% increase in myofiber number. In regenerating muscles of MCK-CnA{alpha}* mice, myofiber number was increased by 28%. We previously observed a twofold increase in myofiber number in muscles of CnA{alpha}* mdx (dystrophic) mice (46). Others have reported an ~40% decrease in myofiber number in soleus muscles from CnA{alpha} knockout mice (34). Changes in myofiber number in response to genetic manipulation of calcineurin may be secondary to changes in fiber size (34), or they may be mediated by greater NFATc3 activation (21), since NFATc3 can regulate myofiber number during primary myogenesis (21).

Calcineurin activation may enhance the maturation of regenerating muscle fibers after myotoxic injury through increased MRF expression. In regenerating muscles from MCK-CnA{alpha}* mice, a greater proportion of the muscle cross-sectional area was occupied by viable muscle fibers and less was occupied by noncontractile tissue (inflammatory cell, connective and adipose tissue). Furthermore, the relative recovery of regenerating fiber size was superior. These factors likely contributed to the enhanced recovery of relative sPo in muscles from MCK-CnA{alpha}* mice: 44% of uninjured values compared with 35% in WT mice.

Expression of myogenin and MEF2a is regulated, at least in part, by the calcineurin signal transduction pathway (12, 49, 50). Calcineurin activation increased myogenin expression in regenerating muscles 5 days postinjury. This finding was surprising given that the CnA{alpha}* transgene is driven by the MCK promoter, which is most active in fused myotubes (43). At 9 days postinjury, MEF2a levels were greater in MCK-CnA{alpha}* than in WT mice. In uninjured muscles of adult MCK-CnA{alpha}* and WT mice, myogenin and MEF2a levels were similar. Others have also observed similar levels of MEF2 activation in muscles from CnA-deleted mice and WT mice (33), suggesting that in adult mice, fiber type proportions are set and genetic manipulation of calcineurin does not influence downstream MRF expression. Between 5 and 9 days postinjury, myogenin expression was downregulated in regenerating muscles, and this reduction was twofold greater in MCK-CnA{alpha}* than in WT mice. Within that time frame, MEF2a expression was downregulated in regenerating muscles of WT mice but upregulated in regenerating muscles of MCK-CnA{alpha}* mice. Despite greater MEF2a levels at 9 days postinjury in muscles from MCK-CnA{alpha}* mice, there was no accompanying increase in the levels of developmental MyHC. The more rapid downregulation of myogenin expression and higher levels of MEF2a with no concomitant increase in the levels of developmental MyHC expression suggests that regeneration was accelerated in MCK-CnA{alpha}* compared with WT mice and that MEF2a may have been regulating the expression of slow fiber-specific genes, rather than developmental genes.

The cellular mechanisms responsible for the superior recovery of muscle morphology in regenerating muscles expressing the CnA{alpha}* transgene remains to be elucidated. At 9 days postinjury, the proportion of centrally nucleated myofibers and the number of central nuclei per myofiber were similar in MCK-CnA{alpha}* and WT mice, suggesting that in fast muscles, calcineurin activation may not increase the number of myoblasts fusing to regenerating myofibers. This does not preclude the possibility that secondary fusion occurs sooner in muscles expressing the CnA{alpha}* transgene. A limitation of our "proportion of centrally nucleated fibers" analysis is that it does not account for myofiber number. Although the proportion of centrally nucleated fibers was similar in regenerating TA muscles of MCK-CnA{alpha}* and WT mice, total myofiber number was ~28% greater, and the number of centrally nucleated fibers (i.e., the fusion index) was ~24% greater, in muscles of MCK-CnA{alpha}* compared with WT mice. This raises the issue of whether the proportion of centrally nucleated fibers or the fusion index is a more valid measure for assessing the effect of calcineurin activation on myoblast fusion. Calcineurin activation could enhance secondary myoblast fusion in regenerating muscles through the NFATc2 and IL-4 pathway (17, 18).

We did not detect any deleterious side effects of calcineurin activation in skeletal muscle. In cardiac muscle, depending on the experimental model, calcineurin activation can either inhibit or enhance apoptosis (27). Cardiomyopathy has been observed in transgenic mice expressing a constitutively active calcineurin transgene (23). Some of these effects have been attributed to mitochondrial dysfunction and elevated superoxide production (39). Mitochondrial biogenesis is a crucial regulatory event during muscle regeneration. In regenerating rat muscles, the most prominent increase in mitochondrial respiratory capacity occurs between 5 and 9 days post myotoxic injury, presumably to coincide with the increased metabolic cost of regeneration (8). In our study, differences in regeneration efficacy between MCK-CnA{alpha}* and WT mice became apparent between 5 and 9 days post injury, making it unlikely that regeneration was compromised by mitochondrial dysfunction or increased reactive oxygen species production. The superior fatigue resistance and increased fatty oxidation capacity of muscles from MCK-CnA{alpha}* compared with WT mice (37) offer further indirect support for normal mitochondrial function with calcineurin activation in skeletal muscle. Nonetheless, the possibility that calcineurin activation could increase oxidative stress in regenerating skeletal muscles is interesting and worthy of further examination.

In conclusion, activation of the calcineurin signal transduction pathway enhanced regeneration in muscles after myotoxic injury and promoted recovery of force-producing capacity. The cellular mechanisms responsible for the improvement in muscle structure and the enhanced recovery of fiber size have yet to be elucidated and may involve alterations in the timing of the MRFs. In addition, any potential side effects of calcineurin activation need to be assessed carefully (39). Our findings are consistent with the hypothesis that with calcineurin activation, maturation of regenerating myotubes is more effective.


    GRANTS
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
This work was supported by research grants from the National Health & Medical Research Council of Australia (project numbers 350439 and 454561).


    ACKNOWLEDGMENTS
 
Present address for N. Stupka: Institute of Biotechnology (BioDeakin), Deakin University, Geelong, Victoria 3217, Australia (e-mail: nstupka{at}deakin.edu.au).


    FOOTNOTES
 

Address for reprint requests and other correspondence: G. S. Lynch, Dept. of Physiology, The Univ. of Melbourne, Victoria 3010, Australia (e-mail: gsl{at}unimelb.edu.au)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


    REFERENCES
 TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Abbott KL, Friday BB, Thaloor D, Murphy TJ, Pavlath GK. Activation and cellular localization of the cyclosporine A-sensitive transcription factor NF-AT in skeletal muscle cells. Mol Biol Cell 9: 2905–2916, 1998.[Abstract/Free Full Text]
  2. Allen DL, Leinwand LA. Intracellular calcium and myosin isoform transitions. Calcineurin and CAM kinase pathways regulate preferential activation of the IIa myosin heavy chain promoter. J Biol Chem 277: 45323–45330, 2002.[Abstract/Free Full Text]
  3. Allen DL, Sartorius CA, Sycuro LK, Leinwand LA. Different pathways regulate expression of the skeletal myosin heavy chain genes. J Biol Chem 276: 43524–43533, 2001.[Abstract/Free Full Text]
  4. Bigard X, Sanchez H, Zoll J, Mateo P, Rousseau V, Veksler V, Ventura-Clapier R. Calcineurin co-regulates contractile and metabolic components of slow muscle phenotype. J Biol Chem 275: 19653–19660, 2000.[Abstract/Free Full Text]
  5. Delling U, Tureckova J, Lim HW, De Windt LJ, Rotwein P, Molkentin JD. A calcineurin-NFATc3-dependent pathway regulates skeletal muscle differentiation and slow myosin heavy-chain expression. Mol Cell Biol 20: 6600–6611, 2000.[Abstract/Free Full Text]
  6. Delling U, Tureckova J, Lim HW, De Windt LJ, Rotwein P, Molkentin JD. A calcineurin-NFATc3-dependent pathway regulates skeletal muscle differentiation and slow myosin heavy-chain expression. Mol Cell Biol 20: 6600–6611, 2000.[Abstract/Free Full Text]
  7. Dellorusso C, Crawford RW, Chamberlain JS, Brooks SV. Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. J Muscle Res Cell Motil 22: 467–475, 2002.[CrossRef][Web of Science]
  8. Duguez S, Fréasson L, Denis C, Freyssenet D. Mitochondrial biogenesis during skeletal muscle regeneration. Am J Physiol Endocrinol Metab 282: E802–E809, 2002.[Abstract/Free Full Text]
  9. Dunn SE, Burns JL, Michel RN. Calcineurin is required for skeletal muscle hypertrophy. J Biol Chem 274: 21908–21912, 1999.[Abstract/Free Full Text]
  10. Dunn SE, Chin ER, Michel RN. Matching for calcineurin activity to upstream effectors is critical for skeletal muscle fiber growth. J Cell Biol 151: 663–672, 2000.[Abstract/Free Full Text]
  11. Friday BB, Horsely V, Pavlath GK. Calcineurin activity is required for the initiation of skeletal muscle differentiation. J Cell Biol 149: 657–665, 2000.[Abstract/Free Full Text]
  12. Friday BB, Mitchell PO, Kegley KM, Pavlath GK. Calcineurin initiates skeletal muscle differentiation by activating MEF2 and MyoD. Differentiation 71: 214–227, 2003.
  13. Gregorevic P, Williams DA, Lynch GS. Hyperbaric oxygen increases the contractile function of regenerating rat slow muscles. Med Sci Sports Exerc 34: 630–636, 2002.
  14. Gross JG, Morgan JG. Muscle precursor cells injected into irradiated mdx mouse muscle persist after serial injury. Muscle Nerve 22: 174–185, 2005.[CrossRef]
  15. Hoey T, Sun YL, Williamson K, Xu X. Isolation of two new members of the NF-AT gene family and functional characterization of the NF-AT proteins. Immunity 2: 461–472, 1995.[CrossRef][Web of Science][Medline]
  16. Horsely V, Friday BB, Matteson S, Miller Kegley K, Gephart J, Pavlath GK. Regulation of the growth of multinucleated muscle cells by an NFATc2-dependent pathway. J Cell Biol 153: 329–338, 2001.[Abstract/Free Full Text]
  17. Horsely V, Jansen KM, Mills ST, Pavlath GK. IL-4 acts a myoblast recruitment factor during mammalian muscle growth. Cell 113: 483–494, 2003.[CrossRef][Web of Science][Medline]
  18. Horsley V, Pavlath GK. Forming a multinucleated cell: molecules that regulate myoblast fusion. Cells Tissues Organs 176: 67–78, 2004.[CrossRef][Web of Science][Medline]
  19. Horsely V, Pavlath GK. Prostaglandin F2{alpha} stimulated growth of skeletal muscle cells via an NFATC2-dependent pathway. J Cell Biol 161: 111–118, 2003.[Abstract/Free Full Text]
  20. Ishiura S, Nonaka I, Sugita H. Biochemical aspects of bupivacaine-induced acute muscle degeneration. J Cell Sci 83: 197–212, 1986.[Abstract]
  21. Kegley KM, Gephart J, Warren GL, Pavlath GK. Altered primary myogenesis in NFATc3–/– mice leads to decreased muscle size in the adult. Dev Biol 232: 115–126, 2001.[CrossRef][Web of Science][Medline]
  22. Launay T, Noirez P, Butler-Browne GS, Agbulut O. Expression of slow myosin heavy chain during muscle regeneration is not always dependent on muscle innervation and calcineurin phosphatase activity. Am J Physiol Regul Integr Comp Physiol 290: R1508–R1514, 2006.[Abstract/Free Full Text]
  23. Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93: 215–228, 1998.[CrossRef][Web of Science][Medline]
  24. Lynch GS, Hinkle RT, Chamberlain JS, Brooks SV, Faulkner JA. Force and power output of fast and slow skeletal muscles from mdx mice 6–28 month old. J Physiol 535: 591–600, 2001.[Abstract/Free Full Text]
  25. Michel RN, Dunn SE, Chin ER. Calcineurin and skeletal muscle growth. Proc Nutr Soc 63: 341–349, 2004.[CrossRef][Web of Science][Medline]
  26. Mitchell PO, Mills ST, Pavlath GK. Calcineurin differentially regulates maintenance and growth of phenotypically distinct muscles. Am J Physiol Cell Physiol 282: C984–C992, 2002.[Abstract/Free Full Text]
  27. Molkentin JD. Calcineurin, mitochondrial membrane potential, and cardiomyocyte apoptosis. Circ Res 88: 1220–1222, 2001.[Free Full Text]
  28. Musaro A, McCullagh KAJ, Naya FJ, Olson EN, Rosenthal N. IGF-I induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nature 400: 581–585, 1999.[CrossRef][Medline]
  29. Naya FJ, Mercer B, Shelton JM, Richardson JA, Williams SR, Olson EN. Stimulation of slow skeletal muscle fiber gene expression by calcineurin in vivo. J Biol Chem 275: 4545–4548, 2000.[Abstract/Free Full Text]
  30. Naya FJ, Olson EN. MEF2: a transcriptional target for signaling pathways controlling skeletal muscle growth and differentiation. Curr Opin Cell Biol 11: 683–688, 1999.[CrossRef][Web of Science][Medline]
  31. Oh M, Rybkin II, Copeland V, Czubryt MP, Shelton JM, Van Rooij E, Richardson JA, Hill JA, De Windt LJ, Bassel-Duby R, Olson EN, Rothermel BA. Calcineurin is necessary for the maintenance but not embryonic development of slow muscle fibers. Mol Cell Biol 25: 6629–6638, 2005.[Abstract/Free Full Text]
  32. Olson EN, Williams SR. Calcineurin signaling and muscle remodeling. Cell 101: 689–692, 2000.[CrossRef][Web of Science][Medline]
  33. Parsons SA, Millay DP, Wilkins BJ, Bueno OF, Tsika GL, Neilson JR, Liberatore CM, Yutzey KE, Crabtree GR, Tsika RW, Molkentin JD. Genetic loss of calcineurin blocks mechanical overload-induced skeletal muscle fiber-type switching but not hypertrophy. J Biol Chem 2004.
  34. Parsons SA, Wilkins BJ, Bueno OF, Molkentin JD. Altered skeletal muscle phenotypes in calcineurin A{alpha} and Abeta gene-targeted mice. Mol Cell Biol 23: 4331–4343, 2003.[Abstract/Free Full Text]
  35. Rauch C, Loughna PT. Static stretch promotes MEF2A nuclear translocation and expression of neonatal myosin heavy chain in C2C12 myocytes in a calcineurin- and p38-dependent manner. Am J Physiol Cell Physiol 288: C593–C605, 2005.[Abstract/Free Full Text]
  36. Rosenblatt JD, Woods RI. Hypertrophy of rat extensor digitorum longus muscle injected with bupivacaine. J Anat 181: 11–27, 1992.[Web of Science][Medline]
  37. Ryder JW, Bassel-Duby R, Olson EN, Zierath JR. Skeletal muscle reprogramming by activation of calcineurin improves insulin action on metabolic pathways. J Biol Chem 278: 44298–44304, 2004.[CrossRef][Web of Science]
  38. Sakuma K, Nishikawa J, Nakao R, Watanabe K, Totsuka T, Nakano H, Sano M, Yasuhara M. Calcineurin is a potent regulator for skeletal muscle regeneration by association with NFATc1 and GATA-2. Acta Neuropathol (Berl) 105: 271–280, 2003.[Medline]
  39. Sayen MR, Gustafsson Å, Sussman MA, Molkentin JD, Gottlieb RA. Calcineurin transgenic mice have mitochondrial dysfunction and elevated superoxide production. Am J Physiol Cell Physiol 284: C562–C570, 2003.[Abstract/Free Full Text]
  40. Schertzer JD, Lynch GS. Comparative evaluation of IGF-I gene transfer and IGF-I protein administration for evaluating skeletal muscle regeneration after injury. Gene Ther 13: 1657–1664, 2006.[CrossRef][Web of Science][Medline]
  41. Schiaffino S, Serrano AL. Calcineurin signaling and neural control of skeletal muscle fiber type and size. Trends Pharmacol Sci 23: 569–575, 2002.[CrossRef][Medline]
  42. Semsarian C, Wu MJ, Ju YK, Marciniec T, Yeoh T, Allen DG, Harvey RP, Graham RM. Skeletal muscle hypertrophy is mediated by a Ca2+-dependent calcineurin signalling pathway. Nature 400: 576–581, 1999.[CrossRef][Medline]
  43. Sternberg EA, Spizz G, Perry MW, Vizard D, Weil T, Olson EN. Identification of upstream and intragenic regulatory elements that confer cell-type-restricted and differentiation specific expression on the muscle creatine kinase gene. Mol Cell Biol 8: 2896–2909, 1988.[Abstract/Free Full Text]
  44. Stupka N, Gregorevic P, Plant DR, Lynch GS. The calcineurin signal transduction pathway is essential for successful muscle regeneration in mdx dystrophic mice. Acta Neuropathol (Berl) 107: 299–310, 2004.[CrossRef][Medline]
  45. Stupka N, Michell BJ, Kemp BE, Lynch GS. Differential calcineurin signalling activity and regeneration efficacy in diaphragm and limb muscles of dystrophic mdx mice. Neuromuscul Disord 16: 337–346, 2006.[CrossRef][Web of Science][Medline]
  46. Stupka N, Plant DR, Schertzer JD, Emerson T, Bassel-Duby R, Olson EN, Lynch GS. Activated calcineurin ameliorates skeletal muscle injury in mdx dystrophic mice. J Physiol. 575: 645–656, 2006[Abstract/Free Full Text]
  47. Talmadge RJ, Otis JS, Rittler MR, Garcia ND, Spencer SR, Lees SJ, Naya FJ. Calcineurin activation influences muscle phenotype in a muscle-specific fashion. BMC Cell Biol 5: 28, 2004.[CrossRef][Medline]
  48. Torgan CE, Daniels MP. Regulation of myosin heavy chain expression during rat skeletal muscle development in vitro. Mol Biol Cell 12: 1499–1508, 2001.[Abstract/Free Full Text]
  49. Wu H, Rothermel BA, Kanatous S, Rosenberg P, Naya FJ, Shelton JM, Hutcheson KA, DiMaio MJ, Olson EN, Bassel-Duby R, Williams SR. Activation of MEF2 by muscle activity is mediated through a calcineurin-dependent pathway. EMBO J 20: 6414–6423, 2001.[CrossRef][Web of Science][Medline]
  50. Xu Q, Yu L, Liu L, Cheung CF, Li X, Yee SP, Yang XJ, Wu Z. p38 Mitogen-activated protein kinase-, calcium-calmodulin-dependent protein kinase-, and calcineurin-mediated signaling pathways transcriptionally regulate myogenin expression. Mol Biol Cell 13: 1940–1952, 2002.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
J. Appl. Physiol.Home page
Y. Oishi, M. Hayashida, S. Tsukiashi, K. Taniguchi, K. Kami, R. R. Roy, and Y. Ohira
Heat stress increases myonuclear number and fiber size via satellite cell activation in rat regenerating soleus fibers
J Appl Physiol, November 1, 2009; 107(5): 1612 - 1621.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
N. Stupka, J. D. Schertzer, R. Bassel-Duby, E. N. Olson, and G. S. Lynch
Stimulation of calcineurin A{alpha} activity attenuates muscle pathophysiology in mdx dystrophic mice
Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2008; 294(3): R983 - R992.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
293/2/R686    most recent
00612.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stupka, N.
Right arrow Articles by Lynch, G. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stupka, N.
Right arrow Articles by Lynch, G. S.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.